摘要
目的:探讨氟桂利嗪对精神分裂症患者认知功能障碍的治疗作用。方法:采用双盲对照的方法,对64例功能大体评定量表(AGF)>70分的精神分裂症患者,随机分为研究组和对照组,分别服用氟桂利嗪和安慰剂,疗程12周。在治疗前、治疗12周末应用认知功能评定量表(RBANS)和副反应量表(TESS)评定疗效和不良反应。结果:两组患者治疗前、后比较量表分值均有不同程度增加,对照组仅视觉广度因子有统计学差异(P<0.05),而研究组五个因子及量表总分均有统计学差异(P<0.01),且疗后五个因子及量表总分均较对照组高(P<0.01);两组不良反应差异无显著性(P>0.05)。结论:氟桂利嗪对精神分裂症患者认知功能障碍有治疗作用,安全性较高。
Objective ： To explore the efficacy and side effects of flunarizine in the treatment of cognitive impairment of schizophrenia. Methods：64 cases of schizophrenia with above 70 score of GAF were randomly divided into the observational group and the control group for 12 weeks. The observational group was treated with flunarizine, another with placebo. The clinical efficacy and side effects were evaluated with Repeatable Battery for the Assessment of Neuropsychological Status （RBANS） and treatment emergent symptom scale （TESS） before and after 12 weeks treatment respectively. Results： Both two groups showed that, to some degree, the level of RBANS score were improved. The control group on visual scope has difference factor （ P 〈 0.05 ）. The observational group there were significantly better efficacy on five factor and sum total of RBANS score （ P 〈 0.01 ） and there were significantly better efficacy between the two groups on five factor and sum total of RBANS score （ P 〈 0.01 ） in the observational group than in the control group （P 〈 0.01 ）. There were no significantly difference in side effects between the two groups （P 〉 0.05 ）. Conclusions：flunarizine proves to be effective in the treatment of cognitive impairment of schizophrenia and has better safety.
出处
《中国民康医学》
2007年第23期1019-1020,共2页
Medical Journal of Chinese People’s Health
